Five Nasdaq Micro Caps Announced Reverse Splits in Eight Days. The Rulebook Now Gives Them Fewer Second Chances

by Renée Delacroix · September 3, 2026

Senior Analyst, The MicroCap Herald

Between Aug. 27 and this morning, at least five Nasdaq-listed micro- and nano-cap companies announced reverse stock splits. The ratios span an order of magnitude, the stated reasons range from explicit to absent, and the mechanics for handling fractional shares differ from one to the next. Taken as a group, they illustrate a compliance tool that has become considerably more expensive to use twice.

What was announced

BioRestorative Therapies, Inc. (Nasdaq: BRTX) said on Sept. 2 that it will effect a 1-for-20 reverse split of its common stock effective Sept. 7, 2026, at 4:30 p.m. Eastern time, with split-adjusted trading beginning Sept. 8. The release states the split is aimed at regaining compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. Shares outstanding go from 27,622,556 to approximately 1,381,128; holders otherwise entitled to a fractional share receive one whole share, rounded up; the new CUSIP is 090655705. The company noted that stockholder approval was not required under Nevada law, and that "Every twenty shares of the Company's issued and outstanding Common Stock will automatically convert into one share of Common Stock." BioRestorative develops cell- and tissue-based therapeutic products, including BRTX-100 for chronic lumbar disc disease and its ThermoStem metabolic program.

Wellchange Holdings Company Limited (Nasdaq: WCT) announced this morning a 1-for-5 reverse split of its Class A ordinary shares effective Sept. 8, 2026, reducing the Class A count from approximately 52,905,328 to approximately 10,581,066. Fractional shares round up to the next whole number, the new CUSIP is G9545M131, and the company's Class B ordinary shares are unaffected. The release does not state a reason for the split; it says only that the split affects all shareholders uniformly and will not alter any shareholder's percentage interest except for adjustments resulting from rounding up. Wellchange describes itself as an enterprise software solutions provider headquartered in Hong Kong.

The absence of a stated reason at Wellchange is worth pausing on, because the company's recent listing history runs the other way. Investing.com reported in March that Wellchange regained compliance with the minimum bid price rule after its Class A shares closed at or above $1.00 for at least ten consecutive business days from March 6 through March 19, 2026, with Nasdaq confirming the restoration shortly afterward. That account traces the matter to an initial non-compliance notification dated April 28, 2025, and makes no mention of a reverse stock split being used to cure it. The Herald is not asserting a rationale the company has not given, and is not attributing this week's split to a compliance problem.

Two more landed on Aug. 27. Nexalin Technology, Inc. (Nasdaq: NXL) announced a 1-for-30 reverse split effective Aug. 28 at 5:00 p.m. Eastern, with split-adjusted trading resuming Aug. 31; that release states the split was undertaken "to ensure continued compliance with the Nasdaq bid-price rule." Par value remains $0.001, a new CUSIP of 65345B300 applies, Continental Stock Transfer & Trust Co. is the exchange agent, and stockholders otherwise entitled to a fractional share receive a proportional cash payment rather than a rounded-up share; the release does not give pre- or post-split share counts. Change Agents Corp. (Nasdaq: CHGA) announced a 1-for-20 reverse split effective Aug. 28 at 4:01 p.m. Eastern, also trading split-adjusted from Aug. 31, taking shares outstanding from approximately 21.1 million to approximately 1.05 million and leaving a public float of roughly 930,000 shares. Fractional holders receive one whole share, the new CUSIP is 05344R401, and the company explicitly cited the minimum $1.00 per share bid price requirement in Nasdaq's listing rules.

Tantech Holdings Ltd. (Nasdaq: TANH) rounds out the set with the largest ratio, a 1-for-50 consolidation whose record date is today and whose split-adjusted trading begins tomorrow, taking shares outstanding from 33,382,332 to approximately 667,647. The Herald covers that one separately; the relevant detail here is that it is Tantech's second consolidation since a 1-for-40 split effective Feb. 13, 2025.

Why the second one is the expensive one

A summary published by Sullivan & Worcester describes amendments to Nasdaq Rules 5550(a)(2) and 5450(a)(1) that changed what happens after a reverse split. Under that account, a company that has effected a reverse stock split during the prior one-year period receives no compliance period at all and instead receives an immediate delisting determination, and this applies even if the company was in compliance with the bid price requirement at the time of the earlier split. The summary further states that Nasdaq rules "will not provide for any compliance period in the event the listed company has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one."

A summary from Hunton Andrews Kurth attributes the change to Nasdaq Rule 5810(c)(3)(A), approved by the SEC in October 2024, and states the same two tests in almost the same words: a company is ineligible for any compliance period if it has "(i) effected a reverse stock split over the prior one-year period or (ii) effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to 1." The two summaries agree on the one-year lookback, the two-year window, the 250-to-1 figure and, critically, on the "one or more" construction: a single split large enough to reach 250-to-1 can trigger the cumulative test on its own. None of the five ratios announced in the past week reaches that threshold by itself; Tantech's does in combination with its February 2025 consolidation. Anyone whose decision turns on the precise wording should read the rule directly on Nasdaq's listing center rather than either summary, including this one.

The Hunton summary adds two further points. First, the amendments eliminated the additional compliance period that previously let companies take up to 180 extra days to cure deficiencies created by a reverse split; a company must now cure any secondary deficiency and then meet the minimum price requirement for ten consecutive business days within the initial period. Second, NYSE adopted a parallel framework under Section 802.01C of its Listed Company Manual, approved in January 2025, with a one-year lookback, a 200-to-1 cumulative threshold over two years, and immediate suspension and delisting procedures for companies that fall outside it.

The mechanics also differ more than the headlines suggest, in two ways that matter to small holders. Fractional share treatment is not uniform: BioRestorative, Change Agents and Wellchange all round fractions up to a whole share, preserving odd-lot holders on the register, while Nexalin pays cash in lieu, which can cash out the smallest positions entirely; Tantech's release states that no fractional shares will be created or issued but does not describe the settlement mechanism in the text the Herald reviewed. The second variable is what the split leaves behind. Change Agents expects a public float of roughly 930,000 shares, BioRestorative approximately 1,381,128 shares outstanding, and Tantech approximately 667,647. Nasdaq maintains separate continued-listing standards covering publicly held shares, public holders and the market value of publicly held shares, and a consolidation that fixes a bid-price problem can create pressure against those tests. That is the secondary deficiency scenario the Sullivan & Worcester summary describes, and it now has to be resolved inside the original compliance window.

Index-level context is worth setting aside here. Small-cap benchmarks and companies trading below a dollar are not the same market: these are securities whose listing status, not their sector, is driving the corporate action calendar, and a strong tape does not restore a bid price. The Herald is not reporting intraday or closing prices for any of the companies named here, or index levels alongside them; the US market is open at the time of publication.

The risk framing is the same for every name on this list. A reverse split is an accounting change to the unit of ownership. It does not raise capital, reduce liabilities, or improve operations, and every one of these companies remains a micro- or nano-cap security with the liquidity, spread and volatility characteristics that implies. What the amended rules change is the consequence of failing again: a company that splits and then slips back below a dollar inside the lookback window is, on both firm summaries, looking at a delisting determination rather than another 180 days. Readers should consult each company's own filings on EDGAR before drawing conclusions from any summary, including this one. Nothing here is investment advice.